Roundhill Cannabis ETF

Curaleaf Holdings, Inc. released FY2026 Q1 earnings on May 5 After-Market EST, actual revenue USD 324.23 M (forecast USD 317.05 M), actual EPS USD 0.0895

Curaleaf reports Q1 gross profit of $157.3 million

Curaleaf Holdings Schedules Annual and Special Meeting

Curaleaf Holdings Fully Acquires Four 20 Pharma

Curaleaf Completes Acquisition of Four 20 Pharma to Strengthen European Market Position

Curaleaf Holdings, Inc. to Release FY2026 Q1 Earnings on May 5 After-Market EST, Forecast Revenue USD 317.05 M

US Justice Department Reschedules Marijuana to Schedule III

Curaleaf Holdings, Inc. Launches $83 Million Stock Repurchase Program

Curaleaf Inc stock price gaps down, revenue exceeds expectations

Curaleaf Holdings, Inc. released FY2025 Annual Earnings on February 27 After-Market (EST), Actual Revenue: USD 1.268 B (Forecast: USD 1.274 B), Actual EPS: USD -0.3587

Curaleaf Holdings, Inc. released FY2025 Q4 earnings on February 27 After-Market (EST), actual revenue USD 323.36 M (forecast USD 329.25 M), actual EPS USD -0.0904

Curaleaf Holdings, Inc. to Release FY2025 Q4 Earnings on February 26 After-Market EST, Forecast Revenue USD 328.27 M

Curaleaf Reports Strong Q4 Earnings and Plans to Exit Missouri Market

Curaleaf Holdings, Inc. released FY2025 Q3 earnings on November 6 After-Market (EST), actual revenue USD 320.24 M (forecast USD 316.87 M), actual EPS USD -0.0838

Curaleaf Holdings, Inc. released FY2025 9 Months Earnings on November 6 After-Market EST, with actual revenue of USD 944.77 M and EPS of USD -0.2695

Curaleaf Holdings, Inc. to Release FY2025 Q3 Earnings on November 5 After-Market EST, Forecast Revenue USD 317.11 M

Curaleaf Holdings, Inc. released FY2025 Q2 earnings on August 6 After-Market EST, actual revenue USD 314.52 M (forecast USD 313.92 M), actual EPS USD -0.0839

Curaleaf Holdings, Inc. released FY2025 Semi-Annual Earnings on August 6 After-Market EST, with actual revenue of USD 621.14 M and EPS of USD -0.1874

Curaleaf Holdings, Inc. to Release FY2025 Q2 Earnings on August 6 After-Market EST, Forecast Revenue USD 314.71 M

Curaleaf Holdings, Inc. released FY2025 Q1 earnings on May 8 After-Market EST, actual revenue USD 310.01 M (forecast USD 311.26 M), actual EPS USD -0.0998

InMed Pharmaceuticals

AMPLITECH GROUP INC. USD0.001 S/R 20/11/26 SER B

Amesite

CN Energy

AMPLITECH GROUP INC. COM USD0.001 (S/R 18/07/2026)

NextNRG

Meiwu Tech

Generation Income Properties

MetaVia

OceanPal

MSOS

WEED

CNBS

YOLO

President Trump announced plans to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act, providing a boost to cannabis stocks that have faced significant losses over the past five years. This announcement follows an executive order aimed at increasing funding and research for psilocybin and other substances.

AdvisorShares Pure US Cannabis ETF

Amplify Alternative Harvest ETF

Amplify Seymour Cannabis ETF

AdvisorShares Pure Cannabis ETF

Trump's rescheduling of marijuana is a spark for top marijuana ETFs

MJUS

TOKE

The recent move by the administration to ease federal regulations on medical marijuana is offering substantial tax breaks to numerous cannabis companies. This change has the potential to attract significant investment into the growing sector.

Unusual Whales

Amplify US Alternative Harvest ETF

Cambria Cannabis ETF

New regulations under Trump offer tax breaks for cannabis companies, attracting investment to the growing industry.

MSOX

512690

SNDL (NASDAQ:SNDL) reported a 4.4% year-over-year decline in net revenue to $196 million and a gross profit decrease of 6.8% to $53 million in its Q1 2026 earnings call. The decline was attributed to challenges in the liquor and cannabis markets, alongside working capital management issues. However, the company anticipates profitability improvements from initiatives aimed at generating over $20 million in incremental operating income this year. SNDL is optimistic about future growth, particularly in international sales, and is actively utilizing its share repurchase program due to perceived undervaluation of shares.

benzinga_article

AdvisorShares MSOS 2x Daily ETF

Penghua CSI Alcoholic Drink ETF

SNDL

Full Transcript: SNDL Q1 2026 Earnings Call

Avicanna Inc. has welcomed the U.S. Department of Justice's decision to reschedule certain cannabinoid-based products from Schedule I to Schedule III, aligning with its pharmaceutical strategy. This change is expected to enhance R&D, clinical development, and patient access. The company is advancing its clinical trials, including studies on THC for anxiety and pain management. Avicanna continues to expand its medical cannabis initiatives and is well-positioned to leverage its intellectual property for future U.S. market entry, focusing on pharmaceutical development and strategic partnerships.

StockTitan

iShares US Pharma

Avicanna Welcomes Initial U.S. Rescheduling of Medical Cannabis & Provides Scientific Update | AVCNF Stock News

The cannabis sector is experiencing volatility driven by three key catalysts. Recent federal reforms have led to the rescheduling of medical cannabis, potentially injecting $2 billion into company balance sheets. However, a lawsuit from prohibitionists could create stock weakness. Additionally, the possibility of retroactive tax relief under IRS Rule 280E and a hearing on recreational cannabis rescheduling in mid-2026 could further impact the market. Investors should monitor these developments for potential entry and exit points.

CabotWealthNetwork

Curaleaf Holdings, Inc.

Green Thumb Industries Inc.

3 Catalysts Driving Cannabis Sector Volatility in 2026

The Department of Justice is rescheduling federally approved medical cannabis to Schedule III, which may increase interest from banks and credit unions. This change follows President Trump's executive order and aims to expand access to medical marijuana. The rescheduling could eliminate tax restrictions under Section 280E, improving cash flow for cannabis firms. However, experts warn that new regulations may complicate banking for the industry. The DEA is expediting the rescheduling process, with a hearing set for June 29, 2025, to further discuss the classification of cannabis.

American Banker

SHF HOLDINGS INC C/WTS 28/09/27 (TO PUR COM)

DOJ rescheduling medical cannabis may reignite bank interest

Illinois' cannabis industry may benefit from a federal decision to reclassify marijuana, potentially lowering costs for businesses and facilitating medical research. This reclassification could ease tax burdens and expand research opportunities, as federal officials have recently taken significant steps toward changing marijuana's drug category.

What marijuana reclassification means for Illinois

The American Council of Cannabis Medicine (ACCM) supports the U.S. Department of Justice's decision to reschedule certain marijuana products from Schedule I to Schedule III. This change acknowledges the medical use of FDA-approved cannabis-derived medications and state-licensed medical marijuana programs. The rescheduling is expected to enhance patient access, accelerate research, and reduce barriers for healthcare providers. ACCM emphasizes that this is a foundational step towards integrating medical cannabis into mainstream healthcare, promoting responsible access and innovation in the industry.

prnewswire

13:11 ETAmerican Council of Cannabis Medicine Applauds Federal Cannabis Rescheduling to Schedule III

Rove, a premium cannabis brand, is expanding its Ice Packs line with three new strains—Kiwi Kush, Strawberry Cough, and Frosted Melon—just in time for 4/20. The Ice Packs category has seen a 500% sales growth from Q1 2024 to Q1 2026. These triple-infused pre-rolls are made with premium-grade flower, THCA diamonds, and ice-hash rosin, offering a potent experience. Rove operates in 16 states and has received multiple awards for its products, celebrating its 10-year anniversary in 2026.

12:50 ETRove Expands Ice Packs Line With Three New, Triple-Infused Pre-Roll Strains Ahead of 4/20

BUDZ highlights its valuable legacy genetics portfolio in light of the recent federal Schedule III marijuana action. WEED Inc. (OTCQB:BUDZ) is strategically positioned with rare landrace strains following the Department of Justice's announcement of an immediate Schedule III pathway for qualified medical marijuana products.

BUDZ Highlights Valuable Legacy Genetics Portfolio Following Historic Federal Schedule III Marijuana Action WEED Inc. (OTCQB:BUDZ) Positioned with Rare Landrace Strains as DOJ Announces Immediate Schedule III Pathway for Qualified Medical Marijuana Products | BUDZ Stock News

Roundhill Cannabis ETF(WEED.US)